Meeting Banner
Abstract #2571

Ex vivo ultra-high-field 9.4-Tesla magnetic resonance elastography (MRE) in comparison to whole-mount pathology for improved prostate cancer diagnostics.

Rolf Otto Reiter1,2, Shreyan Majumdar1, Steven Kearney1, Thomas Royston1, Brandon Caldwell3, Rong-Wen Tain4, Kejia Cai4, Cristian Luciano1, Andre Kajdacsy-Balla5, Winnie Mar4, Michael Abern3, and Dieter Klatt1

1Richard and Loan Hill Department of Bioengineering, University of Illinois at Chicago, Chicago, IL, United States, 2Department of Radiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, 3Department of Urology, University of Illinois at Chicago, Chicago, IL, United States, 4Department of Radiology, University of Illinois at Chicago, Chicago, IL, United States, 5Department of Pathology, University of Illinois at Chicago, Chicago, IL, United States

Despite the success of multiparametric magnetic resonance imaging (mpMRI) for the assessment of prostate cancer, it suffers from limitations such as a moderate inter-reader reliability and sub-optimal diagnostic accuracy. This is the first study for the assessment of 6 human prostate specimens without pathology fixation or prior radiation therapy using ex vivo 9.4-Tesla magnetic resonance elastography (MRE). Using whole-mount pathology as a reference, preliminary results show a sensitivity and specificity of 86 % and 52 %, respectively. MRE has the potential to improve the differentiation of benign prostatic hyperplasia nodules from malignant lesions, which is a known limitation of mpMRI.

This abstract and the presentation materials are available to members only; a login is required.

Join Here

Abstract